Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements
暂无分享,去创建一个
Ross J. Harris | J. Sterne | A. Mocroft | R. Hogg | H. Furrer | T. Sterling | M. Saag | J. Rockstroh | E. Lanoy | D. Costagliola | M. May | A. Justice | A. Monforte | F. de Wolf | G. Chêne | J. Gill | L. Force | P. Khaykin | Andrew Phillip
[1] Michael J Silverberg,et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.
[2] Stephen R Cole,et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies , 2009, The Lancet.
[3] A. Phillips,et al. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity , 2009, BMJ : British Medical Journal.
[4] R. Weber,et al. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] P. Reiss,et al. Immunologic, Virologic, and Clinical Consequences of Episodes of Transient Viremia During Suppressive Combination Antiretroviral Therapy , 2008, Journal of acquired immune deficiency syndromes.
[6] JD Lundgren,et al. Loss to follow‐up in an international, multicentre observational study , 2008, HIV medicine.
[7] A. Westfall,et al. Clinical inertia in the management of low-density lipoprotein abnormalities in an HIV clinic. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] Gemma Navarro,et al. Determinants of HIV Progression and Assessment of the Optimal Time to Initiate Highly Active Antiretroviral Therapy: PISCIS Cohort (Spain) , 2008, Journal of acquired immune deficiency syndromes.
[9] D. Costagliola,et al. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] A. Mocroft,et al. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score , 2007, AIDS.
[11] JD Lundgren,et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study , 2007, The Lancet.
[12] P. Massip,et al. Long‐term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs , 2007, HIV medicine.
[13] A. Verbon,et al. Effects of Active Treatment Discontinuation in Patients With a CD4+ T-Cell Nadir Greater Than 350 Cells/mm3: 48-Week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN) , 2007, Journal of acquired immune deficiency syndromes.
[14] A. Phillips,et al. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. , 2007, The Journal of antimicrobial chemotherapy.
[15] Richard D Moore,et al. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] Melissa Skanderson,et al. Development and Verification of a “Virtual” Cohort Using the National VA Health Information System , 2006, Medical care.
[17] Sheldon Brown,et al. Veterans Aging Cohort Study (VACS): Overview and Description , 2006, Medical care.
[18] F. Lert,et al. Predictors identified for losses to follow-up among HIV-seropositive patients. , 2006, Journal of clinical epidemiology.
[19] J. Montaner,et al. Becoming a "treatment success": what helps and what hinders patients from achieving and sustaining undetectable viral loads. , 2006, AIDS patient care and STDs.
[20] F. Brun-Vézinet,et al. First-line Highly Active Antiretroviral Regimens in 2001–2002 in the French Hospital Database on HIV: Combination Prescribed and Biological Outcomes , 2006, Antiviral therapy.
[21] M. Egger,et al. Response to Highly Active Antiretroviral Therapy at 6 Months and Long-Term Disease Progression in HIV-1 Infection , 2005, Journal of acquired immune deficiency syndromes.
[22] R. Salamon,et al. Determinants of clinical progression in antiretroviral‐naïve HIV‐infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996–2002 , 2005, HIV medicine.
[23] A. Justice,et al. Evaluation of Multiple Failure Time Analyses of Observational Data in Patients Treated for HIV , 2005, HIV clinical trials.
[24] Bruno Ledergerber,et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes , 2004, The Lancet.
[25] J. Sterne,et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies , 2003, The Lancet.
[26] R. Salamon,et al. Factors Associated with Mortality in Human Immunodeficiency Virus Type 1–Infected Adults Initiating Protease Inhibitor–Containing Therapy: Role of Education Level and of Early Transaminase Level Elevation (APROCO–ANRS EP11 Study) , 2002 .
[27] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.
[28] A. Mocroft,et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. , 2002, The Journal of infectious diseases.
[29] M. Battegay,et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study , 2000, The Lancet.
[30] M. Moroni,et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.
[31] A. Telenti,et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.
[32] A. Mocroft,et al. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor , 1998, AIDS.
[33] J. Rockstroh,et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV‐infected patients , 1997, AIDS.
[34] H. Brodt,et al. Changing incidence of AIDS‐defining illnesses in the era of antiretroviral combination therapy , 1997, AIDS.
[35] J. Phair,et al. Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). , 1994, Journal of acquired immune deficiency syndromes.
[36] John W. Ward,et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.